Business Wire

Volvo EX90 Electric SUV Will Feature Seoul Semiconductor’s SunLike LED Lighting

18.4.2023 16:00:00 EEST | Business Wire | Press release

Share

Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a global optical semiconductor company, has announced that the new Volvo EX90 Electric SUV will feature its SunLike LED lights. This is the first application of the SunLike technology with sun spectrum in production vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005618/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Volvo EX90 featuring the SunLike technology (Left) / Comparative graph of color gamuts between SunLike and general LEDs (Right) (Graphic: Business Wire)

SunLike, developed and mass-produced by Seoul Semiconductor for the first time in the world, is a healthy light technology that replicates natural light, protecting the 24-hour biological cycle of a human body. For the past five years, Seoul Semiconductor carried out multiple clinical trials with Harvard University in the United States, the University of Basel in Switzerland, and Seoul National University in Korea, confirming that the use of the solar spectrum, SunLike, can make improvements in myopia, regenerate cells, improve memory, and replicate natural colors.

NEARSIGHTEDNESS IMPROVEMENT

Not all lights are the same, and not all lightings are the same. The closer it is to natural light, the better it is. Light is a mass of particles with energy, so the longer our eyes are exposed to high levels of blue light with high energy, there is a greater chance of damaging our photoreceptor cells and developing myopia. This is why children in Asia who spend more time indoors than outdoors under natural light have a high prevalence of myopia.

According to the “Recovery From Form-Deprivation Myopia in Chicks Is Dependent Upon the Fullness and Correlated Color Temperature of the Light Spectrum(2020)” by Singapore Eye Research Institute (SERI), myopia can be improved by using SunLike.

CELL REPRODUCTION

Natural light affects sleep as well. Evening sunlight promotes the secretion of melatonin which helps to sleep. They say more than 70% of our 60 trillion body cells regenerate while we sleep. Seoul Semiconductor confirmed through the “Effect of daylight LED on visual comfort, melatonin, mood, waking performance and sleep (2019)” conducted by the University of Basel in Switzerland that SunLike lighting improves sleep quality compared to conventional LEDs.

MEMORY IMPROVEMENT

Getting a good night sleep reduces the possibility of building up toxins in the brain, improving memory and concentration. Seoul Semiconductor confirmed through the “Daytime Exposure to Short Wavelength-Enriched Light Improves Cognitive Performance in Sleep-Restricted College-Aged Adults (2021)” conducted by Harvard Medical School that problem-solving skills improved by 5% and speed increased by 3.2 folds when SunLike lighting was used.

COLOR REPLICATION

Conventional LED with CRI 90 have a 90% color gamut of 14 colors in high CRI 90 (sunlight 100). However, SunLike has a 95% color gamut of all 99 colors. This means that it is closest to the color seen under natural sunlight.

According to Dan Fidgett, Volvo’s head of materials and colors, “By utilising the spectrum of light emitted from the SunLike LEDs, the progressive materials and interior design of the Volvo EX90 stand out more clearly and without colour distortion” Fidgett also added, “Bringing in SunLike LEDs to the interior of the Volvo EX90 is another illustration of our ambition to bring in innovative technology to deliver a renewed premium in-car experience for our customers”.

For all interior light fixtures of Volvo EX90, SunLike will be installed. Already widely used by large museums and art galleries around the world, SunLike LEDs have been used to reveal the color and texture of Pompeii ruins’ murals in Italy.

N. Kobayashi, SunLike’s key developer and Seoul Semiconductor’s technical advisor (former CEO of TMAT), explains, “SunLike is a differentiated, high-quality ‘healthy lighting’ that has all the benefits of natural light. It is widely being used in various places, such as residential spaces where people rest, hospitals that lack outdoor activities, schools where concentration and vision health are important, horticultural greenhouses that require light, etc”.

In addition to Volvo EX90, SunLike will also equip ‘Polestar 3’ which shares the same technology base.

About Seoul Semiconductor

Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 18,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. Seoul’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en, YouTube, LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Seoul Semiconductor Co., Ltd.
Jinseop Jung
+82-1566-2771
jjs8732@seoulsemicon.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye